Geleen – new mRNA/LNP services and manufacturing
Lonza already operates various modalities at the Geleen site, including cell and gene therapy and commercial mRNA/LNP production. In future, the facilities will also host mRNA/LNP process and analytical development labs, as well as clinical cGMP capabilities. The facility will include more than 30,000 square feet of laboratory, cGMP manufacturing and office space. The expansion will support the manufacturing of non-GMP product suitable for formulation development and toxicology studies, as well as cGMP product for early and late-stage clinical trials. The expanded development services at the Geleen (NL) site are expected to come online at the beginning of 2023, with cGMP readiness scheduled in the first quarter 2024.